MY 010
Alternative Names: MY010Latest Information Update: 06 Sep 2026
At a glance
- Originator Mabylon
- Class Antiallergics; Antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 02 Mar 2026 Pharmacodynamics data from preclinical trial in Allergic rhinitis and Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2026)
- 09 Oct 2025 Mabylon plans phase I development for MY 010 in 2027 (Mabylon pipeline, October 2025)
- 09 Sep 2024 Research programme: anti-birch pollen allergy antibodies - Mabylon is available for licensing as of 09 Sep 2024. https://www.mabylon.com/en/Partnering.htm